Bangladesh Leads Least Developed Country Call For IP Waiver
This article was originally published in PharmAsia News
Executive Summary
Mammoth price differentials between patented and locally produced drugs in a country where nearly 25 million people live in extreme poverty are some of the justifications emerging from Bangladesh's promising pharmaceutical industry as the country led Least Developed Country (LDCs) members of the World Trade Organization (WTO) to seek an extension of the transitional period to enforce intellectual property rights on medicines.